Atopic Dermatitis News and Research

RSS

Atopic dermatitis is a long-term skin disease. "Atopic" refers to a tendency to develop allergy conditions. "Dermatitis" means swelling of the skin. Atopic dermatitis is most common in babies and children. But it can happen to anyone. People who live in cities and dry climates may be more likely to get this disease. When children with atopic dermatitis grow older, this problem can improve or go away. But the skin may stay dry and easy to irritate. At other times, atopic dermatitis is a problem in adulthood. You can't "catch" the disease or give it to other people.

Anacor prices initial public offering of common stock

Anacor Pharmaceuticals, Inc. today announced the pricing of its initial public offering of 12,000,000 shares of its common stock at a price of $5.00 per share.

24 Nov 2010

Provectus reports progress in PV-10 program for metastatic melanoma

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, reports continued progress in its compassionate use program for PV-10. The program currently has enrolled more than 40 patients, ten of whom are expanded access patients from the company's Phase 2 trial of PV-10 for metastatic melanoma, as well as more than 30 new patients.

24 Nov 2010

Scientists to present new findings from NIAID-funded research at ACAAI Annual Meeting

The 2010 Annual Meeting of the American College of Allergy, Asthma & Immunology (ACAAI) brings together leading allergists and immunologists from around the world.

12 Nov 2010

Provectus holds second meeting with Australian TGA to review approval of PV-10 for metastatic melanoma

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, has held its second meeting with the Australian Therapeutic Goods Administration ("TGA") to discuss milestones for approval of PV-10 for treatment of metastatic melanoma. The TGA is the part of the Australian Government's Department of Health and Ageing responsible for the assessment, approval and monitoring of therapeutic goods available in Australia. The initial meeting with the TGA was held in October 2008.

9 Nov 2010

bitop includes first patient in Ectoin inhalation solution clinical trial for inflammation and airway obstruction

bitop AG, a biotech company specializing in the development of Ectoin®-containing medical devices, announced the inclusion of the first patient into a clinical trial on the Ectoin inhalation solution in patients with inflammation and airway obstruction.

8 Nov 2010

Provectus presents PV-10 Phase 2 clinical trial data for metastatic melanoma at Sydney Congress

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, presented positive preliminary data from fully monitored study data for the entire study population of 80 subjects in its Phase 2 clinical trial of PV-10 for metastatic melanoma.

8 Nov 2010

ZymoGenetics announces positive survival data from IL-21 Phase 2a clinical trial

ZymoGenetics, Inc. today announced positive survival data from a Phase 2a clinical trial in metastatic melanoma with recombinant Interleukin 21 (IL-21) as a single agent. Median overall survival was 12.4 months, and the percentage of patients surviving at 12 months was 53%.

29 Sep 2010

NIAMS awards $684,000 SBIR grant to Signum Biosciences to develop GPCR modulating therapeutics

Signum Biosciences, Inc. was recently awarded two Small Business Innovation Research (SBIR) Phase I grants by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), a division of the NIH, totaling over $684,000 for development of novel G-protein coupled receptor (GPCR) modulating therapeutics designed to treat common skin disorders.

20 Sep 2010

Provectus completes enrollment in first cohort of PV-10 Phase 1 trial for liver cancer

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, announced today that it has completed enrollment in the first of two dose cohorts in its Phase 1 clinical trial of PV-10 for liver cancer, and that the therapy was very well tolerated by all three subjects treated, with substantial evidence of efficacy.

15 Sep 2010

Cetaphil launches Restoraderm for management of eczema and atopic dermatitis skin

The Cetaphil® brand, the #1 dermatologist-recommended brand of cleansers and moisturizers announced the launch of Cetaphil® Restoraderm® products, formulated specifically for the needs of eczema and atopic dermatitis skin. Cetaphil® Restoraderm® Skin Restoring Body Wash and Skin Restoring Moisturizer soothes itching associated with skin affected by eczema and atopic dermatitis.

14 Sep 2010

Provectus's PV-10 Phase 2 data to be presented at 7th International Melanoma Research Congress

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, announces that data from its Phase 2 PV-10 metastatic melanoma study will be presented at the 7th International Melanoma Research Congress in Sydney, Australia, on November 4, 2010 at 4:30 p.m., as part of the 4th Interdisciplinary Melanoma & Skin Cancer Centres Meeting,

13 Sep 2010

Anacor Pharmaceuticals files registration statement with U.S. SEC for initial public offering

Anacor Pharmaceuticals, Inc. today announced that it has filed a registration statement with the U.S. Securities and Exchange Commission ("SEC") relating to the proposed initial public offering of shares of its common stock. The number of shares to be offered and the price range for the offering have not yet been determined. All shares of the common stock to be sold in the offering will be offered by Anacor.

13 Sep 2010

NIH announces award to improve human microbiome research

The National Institutes of Health today announced it has awarded approximately $42 million to expand the scope of eight demonstration projects designed to link changes in the human microbiome to health and disease.

8 Sep 2010

Occupational exposure to substances is a major risk factor for neurodermatitis

A child who can't stop scratching himself may well be suffering from atopic dermatitis, also known as neurodermatitis. Extreme irritability of the skin with a concomitant urge to scratch is typical of the disorder. The condition often appears during the first year of life and is on the increase in industrialized countries.

8 Sep 2010

Bristol-Myers Squibb signs definitive agreement to acquire ZymoGenetics

Bristol-Myers Squibb Company and ZymoGenetics, Inc. announced today that the companies have signed a definitive agreement providing for the acquisition of ZymoGenetics by Bristol-Myers Squibb, for $9.75 per share in cash.

8 Sep 2010

Intendis granted rights to KYTHERA's ATX-101 candidate for minimally-invasive fat reduction outside US, Canada

KYTHERA Biopharmaceuticals, Inc. and Intendis, Bayer HealthCare's dermatology business, today announced that they have entered into a licensing agreement granting Intendis rights to KYTHERA's lead product candidate, ATX-101, outside of the US and Canada. ATX-101, a first-in-class investigational drug, is currently in clinical development for the reduction of localized fat under the chin (submental fat).

31 Aug 2010

ZymoGenetics completes enrollment in Phase 2b PEG-IFN lambda clinical trial

ZymoGenetics, Inc. today announced enrollment has been completed in the Phase 2b clinical trial with PEG-Interferon lambda and ribavirin in chronic hepatitis C virus (HCV) infection.

25 Aug 2010

ZymoGenetics second-quarter net loss declines to $3.8 million

ZymoGenetics, Inc. today reported substantially improved financial results for the quarter ended June 30, 2010. For the second quarter of 2010, the company's net loss declined to $3.8 million, or $0.04 per share, a $23.2 million improvement from the $27.0 million loss, or $0.39 per share, reported for the second quarter of 2009. The improvement resulted from higher revenues as well as reduced operating expenses.

4 Aug 2010

Regeneron second-quarter total revenues increase to $115.9 million

Regeneron Pharmaceuticals, Inc. announced financial and operating results for the second quarter of 2010. The Company reported a net loss of $25.5 million, or $0.31 per share (basic and diluted), for the second quarter of 2010 compared with a net loss of $14.9 million, or $0.19 per share (basic and diluted), for the second quarter of 2009.

28 Jul 2010

National Jewish Health receives $31M NIH contract to study skin infections associated with atopic dermatitis

The National Institute of Allergy and Infections Disease has awarded a five-year $31 million contract to National Jewish Health, which is leading a consortium of academic medical centers seeking to better understand skin infections associated with atopic dermatitis. The researchers will focus on antibiotic-resistant staphylococcus aureus (MRSA) infections and widespread viral infections of the skin, both of which are more prevalent among atopic dermatitis patients.

23 Jul 2010

Atopic Dermatitis News and Research

Further Reading

Anacor prices initial public offering of common stock

Provectus reports progress in PV-10 program for metastatic melanoma

Scientists to present new findings from NIAID-funded research at ACAAI Annual Meeting

Provectus holds second meeting with Australian TGA to review approval of PV-10 for metastatic melanoma

bitop includes first patient in Ectoin inhalation solution clinical trial for inflammation and airway obstruction

Provectus presents PV-10 Phase 2 clinical trial data for metastatic melanoma at Sydney Congress

ZymoGenetics announces positive survival data from IL-21 Phase 2a clinical trial

NIAMS awards $684,000 SBIR grant to Signum Biosciences to develop GPCR modulating therapeutics

Provectus completes enrollment in first cohort of PV-10 Phase 1 trial for liver cancer

Cetaphil launches Restoraderm for management of eczema and atopic dermatitis skin

Provectus's PV-10 Phase 2 data to be presented at 7th International Melanoma Research Congress

Anacor Pharmaceuticals files registration statement with U.S. SEC for initial public offering

NIH announces award to improve human microbiome research

Occupational exposure to substances is a major risk factor for neurodermatitis

Bristol-Myers Squibb signs definitive agreement to acquire ZymoGenetics

Intendis granted rights to KYTHERA's ATX-101 candidate for minimally-invasive fat reduction outside US, Canada

ZymoGenetics completes enrollment in Phase 2b PEG-IFN lambda clinical trial

ZymoGenetics second-quarter net loss declines to $3.8 million

Regeneron second-quarter total revenues increase to $115.9 million

National Jewish Health receives $31M NIH contract to study skin infections associated with atopic dermatitis

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News